Impact of the STK11/KRAS co-mutation on the response to immunotherapy in a real-world pan-cancer cohort
Tumori Journal · 2024
DOI: 10.1177/03008916231204441 ↗Kurz gefasst
Fachartikel in der Zeitschrift Tumori Journal, 2024. Verfasst von Andrea Olsen und 7 weiteren Autor:innen. Beteiligte Einrichtung: OncoAtlas, LLC, Moscow, Russia. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Immunotherapy, Lung Neoplasms, Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Introduction
Immune checkpoint inhibitors are highly effective in treating various cancers. We analyzed the significance of the KRAS/STK11 co-mutation in relation to the efficacy of immune checkpoint inhibitors in pan-cancer patient cohort.
Methods
We analyzed data from open-access research: MSK-IMPACT (molecular profiling data from patients receiving systemic antitumor therapy) and MSK-TMB (molecular profiling data from patients receiving immune checkpoint inhibitors). In both studies, high throughput sequencing was used for molecular profiling.
Results
A total of 10,336 patients receiving antitumor therapy (MSK-IMPACT study) and 1661 patients receiving immune checkpoint inhibitors (MSK-TMB study) were included in the analysis. Co-mutation STK11/KRAS was found in 156 (1.5%) and 46 (2.8%) patients in the two studies, respectively. Most patients with the STK11/KRAS co-mutation had non-small cell lung cancer (83% and 85% in the two studies, respectively). Among non-small cell lung cancer patients, the STK11 mutation was associated with a worse outcome for patients receiving systemic antitumor therapy, but not immune checkpoint inhibition therapy (HR for OS 1.90 [95% CI 1.36-2.65] and 1.44 [95% CI 0.88-2.37]). Co-mutation STK11/KRAS was also not associated with patient outcome in any of the studies (HR for OS 0.93 [95% CI 0.56-1.52] and 1.09 [95% CI 0.54-2.19]). High tumor mutational burden was associated with better outcome in the cohort of patients receiving immune checkpoint inhibitors. An analogous analysis among patients in the pan-cancer cohort (excluding patients with non-small cell lung cancer) showed STK11 mutations and high tumor mutational burden have a predictive role for the efficacy of immune checkpoint inhibitors, but not STK11/KRAS co-mutation.
Conclusions
Co-mutation STK11/KRAS is common among patients with non-small cell lung cancer and is not an independent predictive marker for the efficacy of immune checkpoint inhibitors. Further studies are required to clarify the role of STK11 mutations in immune checkpoint inhibitor treatment response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- OncoAtlas, LLC, Moscow, Russia.
- Pirogov Russian National Research Medical University, Moscow, Russia.
- IM Sechenov First Moscow State Medical University, Moscow, Russia.
- Research and Counseling Department, Research Centre for Medical Genetics, Moscow, Russia.
- Department of Oncogenetics, Institute of Higher and Additional Professional Education, Research Centre for Medical Genetics, Moscow, Russia.
- Moscow Institute of Physics and Technology, Dolgoprudny, Moscow Region, Russia.
ORCID-Profile: Alexandra Lebedeva, Maxim Ivanov
Zitieren
APA
Olsen, A., Lebedeva, A., Nosova, P., Nikulin, V., Sharova, M., Ignatova, E., Mileyko, V., & Ivanov, M. (2024). Impact of the STK11/KRAS co-mutation on the response to immunotherapy in a real-world pan-cancer cohort. Tumori Journal. https://doi.org/10.1177/03008916231204441
Vancouver
Olsen A, Lebedeva A, Nosova P, Nikulin V, Sharova M, Ignatova E, et al. Impact of the STK11/KRAS co-mutation on the response to immunotherapy in a real-world pan-cancer cohort. Tumori Journal. 2024. doi:10.1177/03008916231204441
BibTeX
@article{Olsen2024,
author = {Olsen, Andrea and Lebedeva, Alexandra and Nosova, Polina and Nikulin, Vladislav and Sharova, Margarita and Ignatova, Ekaterina and Mileyko, Vladislav and Ivanov, Maxim},
title = {Impact of the STK11/KRAS co-mutation on the response to immunotherapy in a real-world pan-cancer cohort},
journal = {Tumori Journal},
year = {2024},
doi = {10.1177/03008916231204441}
}
EUVIMED